Cargando…

Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient

Detalles Bibliográficos
Autores principales:	Froudarakis, Marios E, Briasoulis, Evangelos
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914654/ https://www.ncbi.nlm.nih.gov/pubmed/20630074 http://dx.doi.org/10.1186/1756-0500-3-195

Ejemplares similares

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?
por: Metro, Giulio, et al.
Publicado: (2020)

Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
por: Shiozawa, Toshihiro, et al.
Publicado: (2018)

Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2022)

Chemotherapy in non-small cell lung cancer: opportunities for advancement
por: Akhtari, Mani, et al.
Publicado: (2016)

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib
por: Esposito Abate, Riziero, et al.
Publicado: (2019)

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study
por: Xu, Ziyi, et al.
Publicado: (2022)

Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials
por: Zhao, Lingdi, et al.
Publicado: (2015)

Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer
por: Katayama, Yuki, et al.
Publicado: (2019)

Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer
por: Li, Lingling, et al.
Publicado: (2022)

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Tumor Immune Microenvironment and Immunotherapy in Non-Small Cell Lung Cancer: Update and New Challenges
por: Xing, Shuqin, et al.
Publicado: (2022)

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
por: Yamada, Yutaka, et al.
Publicado: (2021)

Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
por: Sugisaka, Jun, et al.
Publicado: (2023)

Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments
por: Gower, Arjan, et al.
Publicado: (2022)

Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review
por: CHEN, XUEQIN, et al.
Publicado: (2014)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
por: Qian, Chunfa, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis
por: Feng, Yu, et al.
Publicado: (2023)

Case Report: Lack of Control of Diabetes and Weight Gain in a Patient on Initiation and Rechallenge of Therapy With Olanzapine
por: Schwetschenau, Kristen H.
Publicado: (2006)

Single‐cell transcriptome analysis of tumor‐infiltrating B cells reveals their clinical implications in non‐small cell lung cancer
por: Diao, Xia‐Yao, et al.
Publicado: (2020)

Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
por: Ren, Sijia, et al.
Publicado: (2020)

Matched tissue and liquid biopsies for advanced non-small cell lung cancer patients A potentially indispensable complementary approach
por: Hofman, Paul
Publicado: (2023)

Co-mutations in EGFR driven non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2019)

Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
por: Asai, Nobuhiro, et al.
Publicado: (2014)

Minimalistic immunohistochemical approach to non-small cell carcinoma of the lung in small biopsies in the context of the 2015 WHO Classification of Lung Cancer
por: Siddaraju, Neelaiah
Publicado: (2017)

Successful rechallenge with cisplatin following cisplatin induced ischemic cerebrovascular accident in a patient with small cell lung cancer
por: Rashid, Farah, et al.
Publicado: (2022)

Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis
por: Zhai, Wen-Yu, et al.
Publicado: (2022)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
por: Li, Fengtan, et al.
Publicado: (2021)

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
por: Haanen, John, et al.
Publicado: (2020)

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Masuda, Tomomi, et al.
Publicado: (2020)

Single-cell insights into the dynamic tumor microenvironment changes during immunotherapy of non-small cell lung cancer
por: Prazanowska, Karolina Hanna, et al.
Publicado: (2023)

Expression Profiles and Clinicopathologic Features in Early Resected Non-small-cell Lung Cancer()
por: Rosell, Rafael
Publicado: (2014)

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
por: Liu, Xiaoming, et al.
Publicado: (2017)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
por: Giuliani, Jacopo, et al.
Publicado: (2021)

Lung squamous cell carcinoma exhibits a targetable glucose dependency unique among non-small cell lung cancers
por: Goodwin, Justin, et al.
Publicado: (2017)

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib
por: Hotta, Takamasa, et al.
Publicado: (2019)

Surgery for stage IV non-small cell lung cancer?
por: Puig, Carlos A., et al.
Publicado: (2020)

Implications of the success of EGFR-targeted therapy in advanced non–small cell lung cancer for its application to the adjuvant setting
por: Takeda, Masayuki
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ln98fsgku0uhsb9ah51dd6hraa